Physician profile
Daniel P Thompson
NPI 1205047610
$2,342.33
in general payments reported to CMS, 2019-2025
31 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $381 · 2021: $384 · 2022: $527 · 2023: $510 · 2024: $178 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914 · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.19 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $386.88 | 2021-2025 | Avycaz, Teflaro, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $316.80 | 2022-2024 | |
| Glaxosmithkline, LLC. | $169.28 | 2019-2022 | |
| Amgen INC. | $132.68 | 2020-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $132.63 | 2020-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $125.94 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $123.87 | 2022-2023 | Nuzyra |
| Pfizer INC. | $116.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $85.12 | 2020-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.57 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $74.35 | 2019-2022 | |
| Melinta Therapeutics, LLC | $72.80 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.35 | 2020-2021 | |
| Insulet Corporation | $51.19 | 2024-2025 | Omnipod |
| Horizon Therapeutics Plc | $47.35 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $40.49 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $39.34 | 2024-2025 | Ingrezza |
| Allergan, INC. | $37.86 | 2020 | |
| Astellas Pharma US INC | $32.53 | 2022-2023 | Myrbetriq |
| Merck Sharp & Dohme LLC | $30.76 | 2023-2024 | Recarbrio, Zerbaxa, Dificid |
| Kowa Pharmaceuticals America, INC. | $25.81 | 2020-2021 | |
| Biowound Solutions, INC. | $22.95 | 2025 | Bio-Connekt |
| Otsuka America Pharmaceutical, INC. | $19.29 | 2023 | Rexulti |
| Smith+Nephew, INC. | $17.34 | 2022 | |
| Gilead Sciences, INC. | $16.63 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.68 | 2021 | |
| Biogen, INC. | $15.34 | 2021 | |
| Exact Sciences Corporation | $15.11 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $14.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.98 | 2021 | |
| Itamar Medical INC | $3.45 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.